Back to search

Peptide record

TPDB10259

SMP24 Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10259
SMP24
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifungipept CAFPdb APD_complete PD_Hemolysis ToxinPred 3.0
standard
No
A 24-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
IWSFLIKAATKLLPSLFGGGKKDS
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C123H197N29O31
RNCEQHMYV
LK
2578.09
10.55
4
1
11
+3
-0.02
0.313
105.83
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
5500
2.13
4
Residue Composition
number
2
A
0
R
0
N
1
D
0
C
0
E
0
Q
3
G
0
H
2
I
4
L
4
K
0
M
2
F
1
P
3
S
1
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 2 L: 4 K: 4 M: 0 F: 2 P: 1 S: 3 T: 1 W: 1 Y: 0 V: 0
Chemical Descriptors
24 reviewed residue count
C123H197N29O31 sequence-only estimate (linear, free termini)
2578.09 sequence-only estimate (linear, free termini)
10.55 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-0.02 sequence-only estimate (linear, free termini)
0.313 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Scorpio maurus palmatus Egyptian scorpion Scorpio maurus palmatus Activity
Evidence Records 20 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4-8 µg/mL

Target

Staphylococcus aureus SH100

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against B. subtilis NCIMB 8024, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can
Evidence 2 Activity

Activity

MIC
Antibacterial
64 µg/mL

Target

Escherichia coli JM109

Source & Reference

dbAMP DRAMP

Other

tive against B. subtilis NCIMB 8024, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can adopt a helical conformation
Evidence 3 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

4, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can adopt a helical conformation in 60% TFE, laying a basis for m
Evidence 4 Activity

Activity

LC50
LC50 = 16 ± 0.9 µg/mL
Anticancer
16

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 5 Activity

Activity

LC50
LC50 = 16 ± 1.3 µg/mL
Anticancer
16

Target

Leukemia Cancer
KG-1a
Blood

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 6 Activity

Activity

Fig 2
Anticancer

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

LDH leakage assay

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 7 Activity

Activity

Fig 2
Anticancer

Target

Leukemia Cancer
KG-1a
Blood

Assay & Model

LDH leakage assay

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 8 Activity

Activity

IC50
IC50 = 4.06 ± 0.60 µM
Anticancer
4.06

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 9 Activity

Activity

IC50
IC50 = 4.64 ± 0.18 µM
Anticancer
4.64

Target

Lung Cancer
H-3122
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 10 Activity

Activity

IC50
IC50 = 6.34 ± 0.53 µM
Anticancer
6.34

Target

Lung Cancer
PC-9
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 11 Activity

Activity

IC50
IC50 = 7.07 ± 0.81 µM
Anticancer
7.07

Target

Lung Cancer
H-460
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 12 Activity

Activity

IC50
IC50 = 5.524 µM
Anticancer
5.524 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 13 Activity

Activity

MIC
Antifungal
4-8 µg/mL

Target

Staphylococcus aureus SH100

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against B. subtilis NCIMB 8024, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can
Evidence 14 Activity

Activity

MIC
Antifungal
64 µg/mL

Target

Escherichia coli JM109

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

tive against B. subtilis NCIMB 8024, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can adopt a helical conformation
Evidence 15 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

4, S. epidermidis sp., S. aureus SH100 (MIC 4-8 ug/ml), E. coli JM109 (MIC 64 ug/ml), and C. albicans (MIC 32 ug/ml). Structure: The peptide can adopt a helical conformation in 60% TFE, laying a basis for m
Evidence 16 Activity

Activity

5% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 32 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Characterisation of three alpha-helical antimicrobial peptides from the venom of Scorpio maurus palmatus. | Toxicon | 2016
Evidence 17 Activity

Activity

15% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
15% Hemolysis | 64 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Characterisation of three alpha-helical antimicrobial peptides from the venom of Scorpio maurus palmatus. | Toxicon | 2016
Evidence 18 Activity

Activity

52% Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
52% Hemolysis | 128 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Characterisation of three alpha-helical antimicrobial peptides from the venom of Scorpio maurus palmatus. | Toxicon | 2016
Evidence 19 Activity

Activity

90% Hemolysis
Toxicity
512 µg/mL
Hemolytic Cytotoxic
90% Hemolysis | 512 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Characterisation of three alpha-helical antimicrobial peptides from the venom of Scorpio maurus palmatus. | Toxicon | 2016
Evidence 20 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.